AbbVie and Lupus Therapeutics partner for SLE trial recruitment

AbbVie has announced a collaboration with Lupus Therapeutics to increase clinical trial recruitment activities in its systemic lupus erythematosus (SLE) trial.

The alliance is intended for the Phase III clinical programme of AbbVie’s upadacitinib (RINVOQ) in SLE patients.